Gilead Sciences (GILD): Why Splitting GILD Is A Bad Idea - Piper Jaffray

August 19, 2016 8:52 AM EDT
Get Alerts GILD Hot Sheet
Price: $71.91 -1.59%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 10
Trade GILD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Gilead Sciences (NASDAQ: GILD) along with his price target of $108 while shedding light on the myth that breaking up GILD is a good idea.

The analyst believes that breaking up GILD into its HIV and HCV franchises could reduce the hyper-focus on HCV which is distracting the company from a materially undervalued and robust HIV business (that includes bictegravir/Descovy). The analyst thinks splitting up the company is a poor idea and the probability of this occurring is negligible.

Separating HIV and HCV will require replication of sales forces, commercial infrastructure, administrative efforts and virology R&D. It would also have to address tax considerations and ex-US cash.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $80.59 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Joshua Schimmer

Add Your Comment